ArticleOncology letters2024

Efficacy and safety of anlotinib combined with S‑1 as a third‑ or later‑line treatment for advanced non‑small cell lung cancer in China: A systematic review and meta‑analysis.

Haonan Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.